Osteoporosis in men has become much more prominent as its prevalence and impact have become apparent. Fractures in men are common and of great importance to both individuals and society. Although in many ways the character of osteoporosis in men is similar to that in women, there are important differences as well. For instance, the rate of morbidity and mortality after a hip fracture is greater in men, probably because of more concomitant illness. The causation of osteoporosis in men and the approach to diagnosis are also somewhat different. Of particular importance is the impact of gonadal insufficiency and the relative roles of androgens and estrogen in male skeletal health. Apparently both sex steroids are essential, but the mechanisms by which each affects bone metabolism are unclear. Approaches to the prevention and therapy of osteoporosis in men have been developed. Evidence supports the effectiveness of vitamin D and calcium supplementation, and bisphosphonates are effective in preventing bone loss and fractures in several situations. New therapies (parathyroid hormone, selective estrogens and androgens) are on the horizon.
Fractures in men
The incidence of all fractures is higher in men than in women from adolescence through middle life [4] (Fig.  1) , and the personal and economic impact of these early life fractures is enormous. Although fractures are frequently considered solely the result of trauma (without a component of skeletal fragility), long-term follow-up of men who sustained traumatic tibial or forearm fractures in early to middle life reveal that they are at much greater risk for later hip fracture. In older men, the incidence of fractures caused by minimal to moderate trauma (particularly in hip and spine) increases rapidly with aging ( Fig. 2) and reflects an increasing prevalence of osteoporosis.
The proximal femur is the most important site of osteoporotic fracture. The incidence of hip fracture rises exponentially in men with aging, as it does in women. It is estimated that approximately 30% of hip fractures worldwide will occur in men [5] , and the number of hip fractures is projected to increase dramatically as the elderly population expands. Perhaps as a result of a higher prevalence of concomitant disease, mortality associated with a hip fracture in elderly men is considerably higher than in women [6] .
Vertebral fracture is also an important sequela of osteoporosis. As in women, the presence of vertebral fracture in men is associated with loss of height, kyphosis, and increased disability [7] . The presence of vertebral deformity has adverse consequences on mortality [6] , and the occurrence of a vertebral fracture indicates a much higher likelihood of sustaining other osteoporotic fractures [8] .
Other fractures (radius/ulna, humerus, pelvis, femoral shaft) share a common epidemiologic pattern. Men experience more of these in youth, but, with unusual exceptions (eg, humerus), the incidence remains relatively stable during mid-life. It is only later (> 75 years) 303 
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Eric S. Orwoll, MD that the incidence of limb fractures begins to rise in men, and it then does so rapidly. Importantly, the occurrence of a distal forearm fracture [9] or a tibial fracture [10] in a man presages a considerably increased risk of subsequent hip fracture, presumably as a result of low bone mass or an increased risk of falling, or both.
Causes of osteoporosis in men
The causes of osteoporosis in men are numerous, and a partial list in given in Table 1 . This topic was recently reviewed [11] , but there are several areas that are particularly interesting in light of recent developments.
Idiopathic (primary) osteoporosis
Although metabolic bone disease in men is traditionally considered to be more commonly related to "secondary" causes, this impression is difficult to substantiate. In fact, osteoporosis may be idiopathic in as many as 50% of the men affected [12] .
The character of idiopathic osteoporosis in men is relatively indistinct. Khosla et al. [13] found that young patients with idiopathic osteoporosis (both men and women) had histomorphometric characteristics suggesting a defect in bone formation, and Marie et al. [14] found that most men with eugonadal osteoporosis had evidence of decreased bone formation. A possible explanation for the osteoblastic defect is a reduction in growth factor action [15] . Several reports suggest that men with idiopathic osteoporosis have relatively low levels of insulin-like growth factor (IGF)-1 or IGF binding protein-3 [16, 17] , a finding that seems to relate to lower histomorphometric indices of osteoblast work. Since there is a relationship between IGF-1 and sex steroid concentrations, an effect of growth factor action and bone may be in part related to sex steroid action as well [18] . It is likely that at least a fraction of the men who present with idiopathic osteoporosis have genetic underpinnings of their disorder. For instance, IGF-1 levels are related to the presence of polymorphisms in the IGF-1 gene [19] . Other genes have also been implicated as a cause of lower bone mass [20•], but more definitive studies are needed.
Effects of gonadal function on skeletal health
Sex steroids have major influences on the regulation of bone metabolism. Clinical and basic observations have highlighted the importance of estrogens and androgens in bone physiology in both sexes in several stages of life.
Since adolescence is so important for skeletal maturation, disorders of puberty have the potential to impair peak bone mass development and thus to influence fracture risk throughout adulthood [21] . Testosterone has major effects on calcium kinetics and balance in boys [22] . Strongly supporting the importance of androgen action in the achievement of peak bone mass in men is the fact that genetic males with complete androgen insensitivity (testicular feminization) experience increased pubertal growth but achieve a bone mass less than expected of androgen replete subjects [23•]. The failure to acquire peak bone mass with puberty is the primary abnormality in these forms of early-onset hypogonadism. In fact, constitutionally delayed puberty may be associated with permanent reductions in bone density [24] . Since cortical bone mass is relatively greater in males, androgen action appears especially important in the modeling drifts that add periosteal new bone during growth. Several men with abnormalities of estrogen action, including one man with an abnormal estrogen receptor [25] and two others with aromatase deficiency [26, 27] , have presented in early adulthood with failure of skeletal maturation and low bone mass. These men share several common skeletal characteristics, including unfused epiphyses and low bone density. In men with aromatase deficiency, estrogen replacement rapidly results in a reversal of those defects [27,28•] . From these individuals, it is clear that estrogen is needed for adequate epiphyseal function as well as bone mass development. Of considerable interest, in studies of aromatase knockout mice, Oz et al. [29•] noted that there was a gender difference in the skeletal character.
Androgens may be essential for the maintenance of bone mass in adult men, as the development of hypogonadism in mature men is associated with bone loss and low bone mass. An increasingly important group of men with hypogonadism are those treated with castration or gonadotropin-releasing hormone agonists for prostate disease. In these men, bone loss is rapid and the development of osteoporosis at an accelerated rate can be expected [30] . In addition to the link between primary testicular dysfunction and low bone mass, reduction in gonadal function secondary to several other conditions may contribute to the development of bone loss. For instance, hypogonadism is suspected to contribute to the reduced bone mass associated with glucocorticoid excess, renal insufficiency, and other conditions [31] .
Androgen therapy in hypogonadal men has been shown to positively affect bone mass, at least in most patient groups [32] . The increase in density following testosterone replacement generally appears to be most apparent in cancellous bone (eg, lumbar spine), and usually the increase in bone mass with testosterone therapy has been modest. However, Behre et al. [33] noted an increase in spinal trabecular bone mineral density (BMD) of greater than 20% in the first year of testosterone therapy in a group of hypogonadal men, and further increases thereafter. In addition to the generally positive effects of androgen replacement therapy in hypogonadal men, additional benefits can be gained from the increases that have been noted in strength and lean body mass in these patients [34, 35] . Since lean body mass and strength have been correlated with bone mass and a reduced propensity to fall, they may further serve to promote bone health and reduce fracture risk.
The effects of estrogen on the male skeleton have become of great interest [36, 37] . As noted earlier, estrogen is important in male skeletal development. The cases of young men with estrogen deficiency and marked abnormalities of bone development further raise the issue of whether estrogen is the more important sex steroid. Estrogen has sometimes reported to be positively correlated with bone mineral density [38] or fractures [39•] in older men, even to a greater extent than is testosterone. Some evidence suggests that impairment in estrogen action might underlie idiopathic osteoporosis [40] . Nevertheless, androgens clearly influence the skeleton and probably play an independent, and coordinated, role with estrogens.
An early increase in remodeling after sex steroid withdrawal in men is consistent with recent reports of the biochemical and cellular events that are associated with androgen and estrogen action (a suppression of cytokine production and osteoclast formation). Estrogen deficiency would be expected to result in lower levels of osteoprotegerin [41] , thus increasing osteoclastic bone resorption. The effects of androgen on osteoprotegerin or osteoprotegerin ligand are as yet unknown but also may play a role in the genesis of hypogonadal bone disease. The current model of skeletal metabolism in hypogonadism remains quite incomplete.
Aging in men is associated with changes in the hypothalamic-pituitary-gonadal axis that result in notable declines in testosterone and estradiol levels. Indeed, there have been several attempts to link bone mass to sex steroid levels in older men [42], generally with limited success (the correlation coefficients are generally quite weak). In an attempt to test the hypothesis that relative androgen deficiency has a skeletal impact, Snyder et al. [43••] found that testosterone administration increased spinal BMD slightly in older men. The possible role of estrogen (either of endogenous sources or from the conversion via aromatase from exogenously administered testosterone) obscures the interpretation of this experience. 
Evaluation of osteoporosis and fracture risk in men
In women, BMD is clearly related to fracture risk in both retrospective case-controlled studies and prospective trials. Fewer data are available in men, but those available are consistent with a similar inverse relationship of bone mass to fracture. Hip and spine BMD were found to be clearly reduced in a series of men with hip fracture compared with age-matched control subjects, and more recently several prospective studies have documented the relationship between low BMD measures and increased risk of fracture [44] [45] [46] [47] [48] . In fact, the degree to which low BMD increases fracture risk appears to be similar between men and women.
The diagnostic criteria that should be used to identify men with high fracture risk, and thus in need of intervention, is uncertain. Although it is clear that there is an inverse relationship between bone density and fracture risk, the relationship between bone mineral density and fracture likelihood is not well established in men. Some investigators have suggested that the relationship between the absolute level of bone density and future fracture risk should be the same in men and women [47, 49, 50] , whereas others have noted gender differences [51•]. Until the fracture risk associated with any given level of bone density is established in prospective trials, it may be reasonable to use reference ranges based on gender-specific reference values.
Prevention and therapy
Activity is probably beneficial in several ways for fracture risk reduction. Reductions in strength and coordination contribute to fracture via an increased risk of falling [52] . In addition, inactivity is associated with bone loss, and exercise may increase or maintain bone mass. Specific exercise prescriptions to accomplish these goals have not been confirmed in men or women, although it is clear that strength can be dramatically increased, and risk of falls reduced, in elderly people with achievable levels of exercise. Beck and Marcus [53] recently reviewed the issue of exercise, men, and skeletal health.
An area of obvious interest is the influence of calcium and vitamin D nutrition [54] . Calcium intake is probably important in the achievement of optimal peak bone mass in boys, as well as the prevention and therapy of osteoporosis later in life. Calcium absorption declines with aging in men as in women, particularly after the age of 60, and well-documented changes in mineral metabolism occur concomitantly with age in men [55] . These data suggest that optimal levels of calcium intake may change with age and that inadequate calcium nutrition can have an adverse effect on skeletal mass. An improvement in bone density was noted in healthy older men in response to calcium and vitamin D supplemen-tation, whereas placebo-treated men lost bone [56] . On the basis of the available information, and the likelihood of a high degree of safety, the U.S. Institute of Medicine recently recommended that men over 50 years of age should have a calcium intake of 1200 mg/day and a vitamin D intake of 800 IU.
Bisphosphonates
Few trials of bisphosphonates have been performed exclusively in men, and many have been reported only in preliminary form. Nevertheless, there is no conceptual barrier to the use of bisphosphonates in men, and recent reports describe positive results. In the first large controlled trial of a bisphosphonate (or any therapy) in men with primary osteoporosis, alendronate had positive results on bone mass and reduced the rate of vertebral fracture [57••] (Fig. 3) . These results provide considerable support for the effectiveness of bisphosphonates in men with osteoporosis. Of interest, the increase in bone mass resulting from alendronate therapy was as great as previously reported in postmenopausal women with osteoporosis, and was as great in men who began the trial with low free testosterone levels as in those with normal levels.
Bisphosphonates have also been examined in men with secondary causes of osteoporosis, especially in the context of glucocorticoid therapy. For instance, in a large trial of alendronate in men receiving glucocorticoids, positive effects were noted in lumbar spine BMD [58] . Similar results have been reported in trials with other bisphosphonates (etidronate, residronate) [59, 60] in which the increase in BMD at several skeletal sites, and the tendency toward a reduction in fracture risk, was similar in men and women. There are a variety of other situations in which bisphosphonates may be useful, but little experience is yet available. For instance, inhibitors of bone resorption have been considered attractive in states of immobilization and in inflammatory conditions (eg, rheumatoid arthritis). Men who receive anti-androgen therapy for prostate carcinoma are at risk of bone loss, and antiresorptive therapy may provide some protection for those patients. Some early reports are available in other conditions [61] , and more can be expected as the effects of bisphosphonates in men are further explored.
Parathyroid hormone
Parathyroid hormone therapy for osteoporosis has recently been shown to have great potential in women. Its use is associated with dramatic increases in bone mass with low rates of adverse effects. Parathyroid hormone therapy was actually initially reported in men with osteoporosis, and recently more extensive experience in men indicates that it may have great usefulness [62••]. Its effects on bone mass appear to be particularly prominent in the spine, but lesser increases were noted in other sites as well (eg, proximal femur). Although information concerning the effects of parathyroid hormone therapy on fracture risk is needed, the increase in bone mass is very promising.
New development in sex steroid therapy
Selective estrogen receptor modulators have considerably altered the concept of estrogen replacement therapy in postmenopausal women. Much interest has developed concerning the relevance of these compounds in the treatment of men as well. Animal studies suggest that selective estrogen receptor modulator may have encouraging effects in males [63••], and clinical trials are underway in men. Finally, selective androgen receptor modulators are being developed and promise to be useful as osteoprotective agents while reducing adverse effects on prostate, lipids, and so on [64••] .
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